INTERACT1 was a multicenter , open , blind outcome assessed , randomized controlled trial of intensive ( systolic target < 140mmHg ) vs. guideline-recommended ( systolic target < 180mmHg ) blood pressure ( BP ) lowering in 404 patients with acute ICH .